Fig. 6

PDIA4 confers glioblastoma resistance to anti-angiogenic therapy. A The workflow of animal therapy study. B In vivo GBMs were imaged at 7, 14, 21, and 28 days after the intracranial tumor was implanted using the IVIS system. C Representative HE staining images show the tumor size of xenograft GBM in each group. D Recorded total flux at each time point present tumor size of each nude mice group dynamically. ns P > 0.05; *P < 0.05. E The line chart exhibits the weight variation of nude mice in each group. ns P > 0.05; **P < 0.01. F Kaplan–Meier survival analysis showed the prognosis of each mice group. ns P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001. G The number of anti-angiogenic therapy responder in each group were compared (Chi-square test, p = 0.018). H Representative VEGFA IHC images of each xenograft GBM mice group with different treatment. I Bar plots show the IHC scores of VEGFA in each xenograft GBM mice group with different treatment. ns P > 0.05. J Representative CD31 IHC image of each xenograft GBM mice group with different treatment. K Bar plots show the CD31 + cell number in each xenograft GBM mice group with different treatment. ns P > 0.05; *P < 0.05